PHAXIAM Therapeutics S.A. (PHXM) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
PHAXIAM Therapeutics S.A. (PHXM) trades at $3.10. PHAXIAM Therapeutics S. A. is a biopharmaceutical company focusing on developing treatments for resistant bacterial infections. Market cap: $19.9M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for PHXM: PHXM does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PHXM against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
PHXM: 3/3 scored disciplines lean bearish. Dominant signal: Jim Simons bearish.
How is this calculated? →PHAXIAM Therapeutics S.A. (PHXM) Healthcare & Pipeline Overview
PHAXIAM Therapeutics S.A., a French biopharmaceutical firm, specializes in developing treatments for resistant bacterial infections, including its lead candidate eryaspase targeting pancreatic cancer. The company also focuses on a portfolio of phages against hospital-acquired infections, positioning itself within the competitive biotechnology landscape.
What Is the Investment Thesis for PHXM?
PHAXIAM Therapeutics presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's lead product, eryaspase, is currently in Phase 3 trials for second-line pancreatic cancer, representing a potential near-term catalyst. Positive trial results could significantly increase the company's valuation. However, the company's negative P/E ratio of -0.02 and a substantial negative profit margin of -1771.3% indicate significant financial challenges. The successful development and commercialization of its phage therapy portfolio could provide long-term growth. Investors should closely monitor clinical trial outcomes and the company's ability to secure funding to sustain operations. The high beta of 1.80 suggests significant volatility relative to the market.
Based on FMP financials and quantitative analysis
PHXM Key Highlights
Market capitalization of $19.9M, indicating a small-cap company with potential for growth but also higher risk.
- Negative P/E ratio of -0.02, reflecting current losses and the company's investment in research and development.
- Profit margin of -1771.3%, highlighting the significant expenses associated with clinical trials and drug development.
- Gross margin of 100.0%, suggesting strong potential profitability if products reach commercialization.
- Beta of 1.80, indicating higher volatility compared to the overall market, typical for biotechnology companies.
Who Are PHXM's Competitors?
PHXM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CSCI COSCIENS Biopharma Inc. | $2.72 | +0.00% | $8.57M | 63 |
| DOMH Dominari Holdings Inc. | $2.59 | -4.43% | $58.6M | — |
| ELEV ELEV | $0.36 | -2.12% | $21.6M | 47 |
| KA Kineta, Inc. | $0.57 | -30.77% | $7.05M | 45 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PHXM's Key Strengths?
Novel therapies targeting unmet medical needs.
- Eryaspase in Phase 3 clinical development.
- Portfolio of phage therapies targeting resistant bacteria.
- Experienced management team.
What Are PHXM's Weaknesses?
Limited financial resources.
- High dependence on clinical trial outcomes.
- Negative profitability and cash flow.
- Small market capitalization.
What Could Drive PHXM Stock Higher?
PHXM catalyst: Phase 3 clinical trial results for eryaspase in second-line pancreatic cancer (anticipated within 12-18 months).
- Potential regulatory approval of eryaspase in the United States and Europe (if Phase 3 trials are successful).
- Expansion of the phage therapy portfolio through research and development.
- Strategic partnerships and collaborations with pharmaceutical companies.
- Potential orphan drug designation for eryaspase in specific cancer subtypes.
What Are the Key Risks for PHXM?
Financial-distress signal — its Altman Z-Score of -1.75 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-95.7%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Failure of Phase 3 clinical trials for eryaspase.
- Regulatory rejection of eryaspase.
- Competition from larger pharmaceutical companies with greater resources.
- Difficulty in securing funding to support clinical trials and operations.
- Currency exchange rate fluctuations affecting the value of the ADR.
What Are the Growth Opportunities for PHXM?
- Eryaspase Clinical Development: The successful completion of Phase 3 clinical trials for eryaspase in second-line pancreatic cancer represents a significant growth opportunity. Positive results could lead to regulatory approval and commercialization, potentially capturing a portion of the multi-billion dollar pancreatic cancer treatment market. Timeline: Anticipated data readout within the next 12-18 months.
- Phage Therapy Portfolio Expansion: Developing and expanding the portfolio of phage therapies targeting resistant bacteria offers a long-term growth driver. The increasing prevalence of antibiotic-resistant infections creates a substantial market opportunity for effective phage-based treatments. Timeline: Ongoing research and development with potential for new product launches in the next 3-5 years.
- Strategic Partnerships and Collaborations: Forming strategic partnerships with larger pharmaceutical companies or research institutions can accelerate the development and commercialization of PHAXIAM's products. Collaborations can provide access to funding, expertise, and distribution networks. Timeline: Ongoing efforts to establish partnerships with potential announcements in the next 12-24 months.
- Geographic Expansion: Expanding operations beyond France and the United States into other key markets, such as Europe and Asia, can drive revenue growth. This requires establishing local partnerships and navigating regulatory requirements in each new market. Timeline: Potential expansion into new markets within the next 3-5 years.
- Orphan Drug Designation: Pursuing orphan drug designation for eryaspase in specific cancer subtypes can provide regulatory and commercial advantages, including market exclusivity and tax incentives. This can enhance the attractiveness of the product to potential partners and investors. Timeline: Application and potential approval within the next 12 months.
What Are PHXM's Competitive Advantages?
- Proprietary technology and intellectual property related to eryaspase and phage therapies.
- Clinical trial data demonstrating the efficacy of its products.
- Regulatory exclusivity granted upon approval of its products.
- Expertise in developing and manufacturing phage-based therapies.
What Does PHXM Do?
PHAXIAM Therapeutics S.A., formerly known as ERYTECH Pharma S.A., was founded in 2004 and is headquartered in Lyon, France. The company is dedicated to developing innovative therapies to combat resistant bacterial infections, a growing global health concern. PHAXIAM's primary focus is on eryaspase, a product in Phase 3 clinical development for the treatment of second-line pancreatic cancer. Additionally, eryaspase is in Phase 2 trials for triple-negative breast cancer and second-line acute lymphoblastic leukemia. Beyond eryaspase, PHAXIAM is developing a portfolio of phages targeting resistant and dangerous bacteria such as staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa, which are responsible for a significant portion of hospital-acquired infections. The company operates primarily in France and the United States, seeking to address unmet medical needs in these key markets. The name change to PHAXIAM Therapeutics in June 2023 reflects the company's strategic shift and renewed focus on phage therapy.
What Products and Services Does PHXM Offer?
- Develops eryaspase for the treatment of second-line pancreatic cancer.
- Develops eryaspase for the treatment of triple-negative breast cancer.
- Develops eryaspase for the treatment of second-line acute lymphoblastic leukemia.
- Develops a portfolio of phages targeting resistant staphylococcus aureus bacteria.
- Develops a portfolio of phages targeting resistant escherichia coli bacteria.
- Develops a portfolio of phages targeting resistant pseudomonas aeruginosa bacteria.
- Focuses on treatments for resistant bacterial infections in France and the United States.
How Does PHXM Make Money?
- Develops and patents novel therapies for resistant bacterial infections.
- Conducts clinical trials to demonstrate the safety and efficacy of its products.
- Seeks regulatory approval from agencies like the FDA and EMA.
- Commercializes approved products through direct sales or partnerships.
- Generates revenue through product sales and licensing agreements.
What Industry Does PHXM Operate In?
PHAXIAM Therapeutics operates within the biotechnology industry, a sector characterized by high innovation, intense competition, and significant regulatory hurdles. The rise of antibiotic-resistant bacteria is driving increased demand for novel therapies like phage therapy. PHAXIAM competes with larger pharmaceutical companies and specialized biotech firms. Competitors include ATON, CSCI, DOMH, ELEV and KA. Success depends on clinical trial outcomes, regulatory approvals, and effective commercialization strategies.
Who Are PHXM's Key Customers?
- Hospitals and healthcare providers treating patients with resistant bacterial infections.
- Oncologists treating patients with pancreatic cancer, breast cancer, and leukemia.
- Patients suffering from resistant bacterial infections and cancers.
- Pharmaceutical companies seeking to license or acquire novel therapies.
Forward Outlook
Wall Street analysts project PHAXIAM Therapeutics S.A. revenue of about $0 for fiscal 2026, with EPS near $0.00.
PHXM Valuation & Market Position
With a $19.9M market cap, PHAXIAM Therapeutics S.A. sits in the micro-cap segment of the market.
Key Financial Metrics
Return on equity for PHAXIAM Therapeutics S.A. stands at -95.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -45.8%, showing how much profit it generates from its asset base. A current ratio of 1.06 indicates the company holds enough short-term assets to cover its near-term obligations.
Financial Health
PHAXIAM Therapeutics S.A.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -1.75 places it in the distress zone, a signal of elevated financial risk.
Company Profile
PHAXIAM Therapeutics S.A. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Lyon, FR. The company is led by CEO Eric Soyer. PHXM has traded publicly since 2017.
PHXM Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Novel therapies targeting unmet medical needs.
- Eryaspase in Phase 3 clinical development.
- Portfolio of phage therapies targeting resistant bacteria.
- Experienced management team.
Bear Case
- Limited financial resources.
- High dependence on clinical trial outcomes.
- Negative profitability and cash flow.
- Small market capitalization.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
PHXM Latest News
No recent news available for PHXM.
PHXM Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PHXM.
Price Targets
Wall Street price target analysis for PHXM.
PHXM MoonshotScore
What does this score mean?
The MoonshotScore rates PHXM 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Eric Soyer
CEO
Eric Soyer serves as the CEO of PHAXIAM Therapeutics S.A. His background includes extensive experience in the pharmaceutical and biotechnology industries. He has held leadership positions in various companies, focusing on strategic development, clinical operations, and commercialization. Soyer's expertise spans across multiple therapeutic areas, including oncology and infectious diseases. He is responsible for overseeing the company's overall strategy and operations.
Track Record: Under Eric Soyer's leadership, PHAXIAM Therapeutics has focused on advancing its clinical pipeline, particularly the Phase 3 development of eryaspase. He has also overseen the expansion of the company's phage therapy portfolio. Key milestones include securing funding for clinical trials and establishing strategic partnerships. His focus is on driving the company towards regulatory approval and commercial success.
PHAXIAM Therapeutics S.A. ADR Information Sponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. PHXM is an ADR, meaning it allows U.S. investors to invest in PHAXIAM Therapeutics S.A., a French company, without the complexities of cross-border transactions. The ADR is denominated in U.S. dollars and trades like a domestic stock.
- Home Market Ticker: Euronext Paris, France
- ADR Level: 2
- ADR Ratio: 1:1
PHAXIAM Therapeutics S.A. Healthcare Stock: Key Questions Answered
What does PHAXIAM Therapeutics S.A. do?
PHAXIAM Therapeutics S.A. is a biopharmaceutical company focused on developing treatments for resistant bacterial infections. Its lead product, eryaspase, is in Phase 3 clinical development for second-line pancreatic cancer and Phase 2 for other cancers. The company also develops a portfolio of phages targeting resistant bacteria responsible for hospital-acquired infections. PHAXIAM aims to address unmet medical needs in France and the United States through innovative therapies.
What do analysts say about PHXM stock?
Analyst coverage for PHXM is limited, reflecting its small market capitalization and early stage of development. Key valuation metrics are difficult to assess due to the company's negative earnings and cash flow. Growth considerations center on the successful completion of clinical trials for eryaspase and the potential commercialization of its phage therapy portfolio. Investors should conduct thorough due diligence and consider the high risk associated with biotechnology investments.
What are the main risks for PHXM?
The main risks for PHAXIAM Therapeutics include the potential failure of clinical trials for eryaspase, regulatory hurdles, competition from larger pharmaceutical companies, and difficulty in securing funding. The company's financial position is weak, with negative profitability and cash flow. Investors should be aware of the high risk associated with biotechnology investments, particularly for companies in early stages of development.
What are the key factors to evaluate for PHXM?
Evaluate PHXM on fundamentals, analyst consensus, and risk factors. PHAXIAM Therapeutics presents a high-risk, high-reward investment opportunity within the biotechnology sector. Not financial advice.
How frequently does PHXM data refresh on this page?
PHXM's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven PHXM's recent stock price performance?
PHAXIAM Therapeutics S.A. (PHXM) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel therapies targeting unmet medical needs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PHXM overvalued or undervalued right now?
PHAXIAM Therapeutics S.A. (PHXM) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research PHXM before investing?
Before investing in PHAXIAM Therapeutics S.A. (PHXM), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data may be outdated. Consult recent filings for updated information.
- Analyst coverage is limited, and consensus estimates may not be available.